We have collected information about Antibody Sirna Delivery for you. Follow the links to find out details on Antibody Sirna Delivery.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333408/
Jan 30, 2015 · Delivery of siRNA is a key hurdle to realizing the therapeutic promise of RNAi. By targeting internalizing cell surface antigens, antibody–siRNA complexes provide a possible solution. However, initial reports of antibody–siRNA complexes relied on non-specific charged interactions and have not been broadly applicable.Author: Trinna L. Cuellar, Dwight Barnes, Christopher Nelson, Joshua Tanguay, Shang-Fan Yu, Xiaohui Wen, Suz...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955097/
Sep 18, 2013 · We describe here the development of site-specific antibody-polymer conjugates (APCs) for the selective delivery of small interference RNAs (siRNAs) to target cells. APCs were synthesized in good yields by conjugating an aminooxy-derivatized cationic block copolymer to an anti-HER2 Fab or full length IgG by means of genetically encoded para -acetyl phenylalanine ( p AcF).Author: Hua Lu, Danling Wang, Stephanie Kazane, Tsotne Javahishvili, Feng Tian, Frank Song, Aaron Sellers, B...
https://academic.oup.com/nar/article/43/2/1189/2414709
Dec 30, 2014 · Delivery of siRNA is a key hurdle to realizing the therapeutic promise of RNAi. By targeting internalizing cell surface antigens, antibody–siRNA complexes provide a possible solution. However, initial reports of antibody–siRNA complexes relied on non-specific charged interactions and have not been broadly applicable.Author: Trinna L. Cuellar, Dwight Barnes, Christopher Nelson, Joshua Tanguay, Shang-Fan Yu, Xiaohui Wen, Suz...
https://clincancerres.aacrjournals.org/content/21/6/1383
Mar 15, 2015 · Systemic delivery of antibody–siRNA complexes is feasible as has been demonstrated for an anti-CD7-siRNA construct that was used to treat HIV infection in humanized mice . This construct was based on a scFV single chain antibody with a c-terminal histidine that was coupled to a small cationic peptide via a disulfide bond.Author: Sebastian Bäumer, Nicole Bäumer, Neele Appel, Lisa Terheyden, Julia Fremerey, Sonja Schelhaas, Eva W...
https://www.cell.com/molecular-therapy-family/nucleic-acids/pdf/S2162-2531(16)30103-2.pdf
Antibody-mediated siRNA Delivery Schneider et al 2 addition of nonspecific endosome-modulating agents such as chloroquine.7 The objective of the present work was to evaluate the use-fulness of bsAbs in combination with dynamic polyconjugates (DPCs) or lipid-based nanoparticles (LNPs) for targeted delivery of siRNA.
http://www.nature.com/articles/nbt1101
May 22, 2005 · This study demonstrates the potential for systemic, cell-type specific, antibody-mediated siRNA delivery. Delivery of small interfering RNAs (siRNAs) into cells is a key obstacle to their ...Author: Erwei Song, Pengcheng Zhu, Sang Kyung Lee, Dipanjan Chowdhury, Steven Kussman, Derek M Dykxhoorn, Yi...
https://pubs.acs.org/doi/10.1021/ja4059525
We describe here the development of site-specific antibody–polymer conjugates (APCs) for the selective delivery of small interference RNAs (siRNAs) to target cells. APCs were synthesized in good yields by conjugating an aminooxy-derivatized cationic block copolymer to an anti-HER2 Fab or full-length IgG by means of genetically encoded p-acetyl phenylalanine (pAcF).Author: Hua Lu, Danling Wang, Stephanie Kazane, Tsotne Javahishvili, Feng Tian, Frank Song, Aaron Sellers, B...
https://www.sciencedirect.com/science/article/pii/S0168365916304138
Therefore, antibodies against internalizing receptors have been thought to be a possible targeting ligand for siRNA delivery. There are two types of delivery platforms available: 1) a covalently bound antibody-siRNA conjugate and; 2) a non-covalently bound complex of siRNAs and cationic peptide-modified antibodies . Considering the manufacturing process, antibody siRNA conjugates provide a single entity without optimizing various factors, such as the siRNA…Author: Tsukasa Sugo, Michiko Terada, Tatsuo Oikawa, Kenichi Miyata, Satoshi Nishimura, Eriya Kenjo, Mari Og...
https://stm.sciencemag.org/content/4/130/130ra48.full
Apr 18, 2012 · However, the efficient delivery of siRNAs into cancer cells in vivo remains a major obstacle. An antibody fragment fused to an RNA binding protamine peptide specifically delivered siRNAs and knocked down gene expression in cells bearing a cell surface protein recognized by the antibody.Author: Yan-dan Yao, Tian-meng Sun, Song-yin Huang, Shuang Dou, Ling Lin, Jia-ning Chen, Jian-bin Ruan, Chen...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767100/
Sep 10, 2019 · Monoclonal antibody (mAb) targeting of siRNAs and ASOs has the potential to deliver these drugs to a variety of specific cell and tissue types. However, most conjugation strategies rely on random chemical conjugation through lysine or cysteine residues resulting in conjugate heterogeneity and a distribution of Drug:Antibody Ratios (DAR).Author: Ian J. Huggins, Carlos A. Medina, Aaron D. Springer, Arjen van den Berg, Satish Jadhav, Xianshu Cui,...
Searching for Antibody Sirna Delivery?
You can just click the links above. The data is collected for you.
